[go: up one dir, main page]

WO1990014831A3 - Composition anti-virale de 3'-azido-2',3'-didesoxy-5-methylcytidine - Google Patents

Composition anti-virale de 3'-azido-2',3'-didesoxy-5-methylcytidine Download PDF

Info

Publication number
WO1990014831A3
WO1990014831A3 PCT/US1990/003207 US9003207W WO9014831A3 WO 1990014831 A3 WO1990014831 A3 WO 1990014831A3 US 9003207 W US9003207 W US 9003207W WO 9014831 A3 WO9014831 A3 WO 9014831A3
Authority
WO
WIPO (PCT)
Prior art keywords
methylcytidine
dideoxy
azido
viral composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1990/003207
Other languages
English (en)
Other versions
WO1990014831A2 (fr
Inventor
Chung K Chu
Raymond F Schinazy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
University of Georgia Research Foundation Inc UGARF
Original Assignee
Emory University
University of Georgia Research Foundation Inc UGARF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University, University of Georgia Research Foundation Inc UGARF filed Critical Emory University
Priority to EP90911253A priority Critical patent/EP0476066B1/fr
Priority to DE69031340T priority patent/DE69031340T2/de
Priority to HK98116012.3A priority patent/HK1014660B/en
Publication of WO1990014831A2 publication Critical patent/WO1990014831A2/fr
Publication of WO1990014831A3 publication Critical patent/WO1990014831A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne une composition acheminant une quantité inhibitrice du VIH d'un composé actif de la formule générale (I), dans laquelle R représente OH, monophosphate, diphosphate, ou triphosphate, ou bien un de leurs sels pharmacologiquement acceptables; et dans laquelle le moyen est un support pharmaceutiquement acceptable. Dans le mode de réalisation préféré, on administre une dose efficace de 3'-azido-2',3'-didesoxy-5-methylcitidine, ou ses dérivés, dans un support pharmaceutiquement acceptable, à un patient, pour le traitement du SIDA.
PCT/US1990/003207 1989-06-07 1990-06-06 Composition anti-virale de 3'-azido-2',3'-didesoxy-5-methylcytidine Ceased WO1990014831A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP90911253A EP0476066B1 (fr) 1989-06-07 1990-06-06 Composition anti-virale de 3'-azido-2',3'-didesoxy-5-methylcytidine
DE69031340T DE69031340T2 (de) 1989-06-07 1990-06-06 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
HK98116012.3A HK1014660B (en) 1989-06-07 1990-06-06 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/362,756 US5084445A (en) 1986-05-01 1989-06-07 3'-azido-2',3'-dideoxy-5-methylcytidine
US362,756 1989-06-07

Publications (2)

Publication Number Publication Date
WO1990014831A2 WO1990014831A2 (fr) 1990-12-13
WO1990014831A3 true WO1990014831A3 (fr) 1991-01-24

Family

ID=23427415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/003207 Ceased WO1990014831A2 (fr) 1989-06-07 1990-06-06 Composition anti-virale de 3'-azido-2',3'-didesoxy-5-methylcytidine

Country Status (8)

Country Link
US (1) US5084445A (fr)
EP (1) EP0476066B1 (fr)
JP (1) JP2941942B2 (fr)
AT (1) ATE157252T1 (fr)
DE (1) DE69031340T2 (fr)
DK (1) DK0476066T3 (fr)
ES (1) ES2108014T3 (fr)
WO (1) WO1990014831A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911470B1 (en) 1988-09-22 2005-06-28 Raymond F. Schinazi Polyoxometalate compounds as antiviral agents
JPH07508022A (ja) * 1992-05-13 1995-09-07 リボザイム・ファーマシューティカルズ・インコーポレイテッド ヌクレオチドモノマー類の合成
US5506349A (en) * 1992-05-13 1996-04-09 Ribozyme Pharmaceuticals, Inc. Chemical synthesis of 2', 3'-dideoxycytidine
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
US5824706A (en) * 1994-09-26 1998-10-20 Schinazi; Raymond F. Method, compositions, and apparatus for treating and preventing respiratory viral infections
CA2241255A1 (fr) * 1995-12-22 1997-07-03 East Carolina University Procede de traitement des troubles caracterises par une surexpression de la cytidine-desaminase ou de la desoxycytidine-desaminase
ATE234103T1 (de) * 1997-12-22 2003-03-15 Schering Corp Feste, oral verabreichbare ribavirin dosisformen und verfahren zu deren herstellung
US6194391B1 (en) * 1998-06-24 2001-02-27 Emory University 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol
IL142983A0 (en) 1998-11-05 2002-04-21 Centre Nat Rech Scient Nucleosides with anti-hepatisis b virus activity
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
US20030083304A1 (en) * 2001-10-09 2003-05-01 Smart Robert C. CCAAT/enhancer binding protein-beta (C/EBPbeta) is a molecular target for cancer treatment
CN104667279B (zh) 2008-03-03 2018-10-26 托斯克公司 减少毒性的甲氨蝶呤佐剂及其使用方法
GB201001088D0 (en) 2010-01-23 2010-03-10 Trillion Genomics Ltd Detection
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
CN114276359B (zh) * 2022-01-05 2023-05-05 浙江大学 一种1,2,3,4-四氢苯并[4,5]呋喃[2,3-c]吡啶衍生物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0217580A2 (fr) * 1985-09-17 1987-04-08 The Wellcome Foundation Limited Nucléosides thérapeutiques
WO1988005657A1 (fr) * 1987-01-28 1988-08-11 Chu Chung K Composition anti-retrovirale de 3'-azido-2',3'-didesoxyuridine

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US3755295A (en) * 1969-10-24 1973-08-28 Syntex Corp 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof
US3775397A (en) * 1969-11-12 1973-11-27 Akad Wissenschaften Ddr Novel cytostatic 2',3'-dideoxy-3'-fluoropyrimidine-nucleosides
US3687931A (en) * 1970-03-19 1972-08-29 Syntex Corp Halogenated purine and pyrimidine nucleosides and process therefor
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
DE2627076A1 (de) * 1976-06-16 1977-12-29 Max Planck Gesellschaft Mittel zur inhibierung des zellwachstums
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
US4093715A (en) * 1977-04-28 1978-06-06 Research Corporation 5-Iodo-5'-amino-2',5'-dideoxycytidine and the pharmaceutically acceptable salts thereof
US4093716A (en) * 1977-04-28 1978-06-06 Research Corporation Compositions containing 5-amino-5-deoxythymidine and pharmaceutically acceptable salts thereof
US4128639A (en) * 1977-12-14 1978-12-05 Research Corporation Nitrosourea analogs of thymidine
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4230689A (en) * 1979-05-01 1980-10-28 Sue Choy Hair grooming composition of matter
US4604382A (en) * 1983-01-17 1986-08-05 Research Corporation 3'-amino-2',3'-dideoxycytidine and the pharmacologically acceptable salts thereof
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
DD224490A1 (de) * 1984-04-30 1985-07-10 Adw Ddr Verfahren zur herstellung eines virostatischen mittels
IE56503B1 (en) * 1985-03-16 1991-08-14 Wellcome Found Antiviral nucleosides
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4710492A (en) * 1986-06-23 1987-12-01 Yale University 3'-azido-2',3'-dideoxy-5-halouridine and its use in treating patients infected with retroviruses
US4788181A (en) * 1986-09-29 1988-11-29 The United States Of America As Represented By The Department Of Health And Human Services 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
EP0286825A3 (fr) * 1987-03-18 1989-04-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Utilisation du 3'-fluro-3'-deoxythymidine pour fabriquer un médicament pour le traitement des infections virales
CA1340645C (fr) * 1987-04-17 1999-07-13 Victor E. Marquez Didesoxynucleosides stables en milieu acide, actifs contre les effets cytopathiques du virus de l'immunoeficience humaine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0217580A2 (fr) * 1985-09-17 1987-04-08 The Wellcome Foundation Limited Nucléosides thérapeutiques
WO1988005657A1 (fr) * 1987-01-28 1988-08-11 Chu Chung K Composition anti-retrovirale de 3'-azido-2',3'-didesoxyuridine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bioorg. Khim., volume 12, no. 8, 1986, N.B. Dyatkina et al.: 'Aminonucleosidesand their derivatives. XIV. A general method for synthesis of 3'-azido-2',3'- dideoxynucleosides', pages 1043 - 1053 *
J. Med. Chem., volume 31, no. 10, October 1988, American Chemical Society, P. Herdewijn et al.: 'Synthesis and anti-HIV activity of different sugarmodified pyrimidine and purine nucleosides', pages 2040 - 2048 *
J. Med. Chem., volume 32, no. 3, March 1989, American Chemical Society, C.K. Chu et al.: 'Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells', pages 612 - 617 *
J. Med., volume 31, no. 2, February 1988, American Chemical Society, T.-S. Lin et al.: 'Synthesis and antiviral activity of varios 3' - azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV- III/LAV)', pages 336 - 340 *
Mol. Biol., volume 22, no. 3, 1988, G.A. Galegov et al.: 'Action of 3'-azido-3'-deoxynucleosodes on aids virus reproduction in cell culture', pages 802 - 806 *

Also Published As

Publication number Publication date
JPH05504940A (ja) 1993-07-29
US5084445A (en) 1992-01-28
EP0476066B1 (fr) 1997-08-27
ATE157252T1 (de) 1997-09-15
WO1990014831A2 (fr) 1990-12-13
EP0476066A1 (fr) 1992-03-25
DK0476066T3 (da) 1997-09-22
DE69031340D1 (de) 1997-10-02
JP2941942B2 (ja) 1999-08-30
HK1014660A1 (en) 1999-09-30
DE69031340T2 (de) 1998-01-15
ES2108014T3 (es) 1997-12-16

Similar Documents

Publication Publication Date Title
WO1990014831A3 (fr) Composition anti-virale de 3'-azido-2',3'-didesoxy-5-methylcytidine
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
IL100502A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside analogues
CA2278290A1 (fr) Composes de quinazolinone
EP0430045A3 (en) Ascorbic acid tocopheryl phosphate diesters for inhibition of maillard's reaction
CA2053826A1 (fr) Compositions pharmaceutiques permettant de traiter les affections neurologiques chez des malades atteints du sida
IL90166A0 (en) Purine derivatives and use thereof in therapy
EP0620004A4 (fr) Compositions medicinales.
CA2003289A1 (fr) Utilisation de (trifluoromethyl) phenyl) terahydropyridines pour la preparation de compositions pharmaceutiques utiles dans le traitement de l'anxiete et des troubles anxio-depressifs
MY124465A (en) Reduction of infarct volume using citicoline
IE892654L (en) Therapeutic nucleosides
AU8447991A (en) Antineoplastic effect potentiator and antineoplastic agent
IL93594A0 (en) Pharmaceutical compositions containing an imidazopyrimidone derivative
NO894325D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrrolidin-derivater.
IL111138A (en) Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia
GB8608893D0 (en) D-nor-7-ergoline derivatives
WO1987003590A1 (fr) Medicament pour le traitement des maladies du foie
RU94045140A (ru) Фармацевтическая композиция для профилактики или лечения вирусных заболеваний, способ ее получения и применение антагониста брадикинина или его физиологически переносимой соли в качестве средства для профилактики или лечения вирусных заболеваний
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
CY2337B1 (en) Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 invection.
IL107818A (en) Pharmaceutical compositions for treating viral infections by conjunctive therapy with acylovir-like compounds and a 2'-(halo) methylene nucleoside analog
AU7506591A (en) A therapeutic agent for dysuria comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives
CY2338B1 (en) Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections.
MY110769A (en) Controlled release oxycodone compositions.
EP0272849A3 (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990911253

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990911253

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1990911253

Country of ref document: EP